{
    "nct_id": "NCT03635983",
    "official_title": "A Phase 3, Randomized, Open-label Study of NKTR-214 Combined With Nivolumab Versus Nivolumab in Participants With Previously Untreated Unresectable or Metastatic Melanoma",
    "inclusion_criteria": "* Eastern Cooperative Oncology Group (ECOG) performance status of ≤1 (adults 18 years or older)/Lansky Performance Score ≥ 80% (minors ages 12-17 only)\n* Histologically confirmed stage III (unresectable) or stage IV melanoma\n* Treatment-naive participants (ie, no prior systemic anticancer therapy for unresectable or metastatic melanoma) with the exception of prior adjuvant and/or neoadjuvant treatment for melanoma with approved agents\nHealthy volunteers allowed\nMust have minimum age of 12 Years",
    "exclusion_criteria": "* Active brain metastases or leptomeningeal metastases\n* Uveal melanoma\n* Participants with an active, known or suspected autoimmune disease\n\nOther protocol defined inclusion/exclusion criteria apply",
    "miscellaneous_criteria": ""
}